Ignite Creation Date:
2025-12-24 @ 6:35 PM
Ignite Modification Date:
2026-02-21 @ 9:53 PM
Study NCT ID:
NCT03777657
Status:
COMPLETED
Last Update Posted:
2025-02-14
First Post:
2018-11-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Sponsor:
BeiGene
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
BGB-A317-305
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None